Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
VRTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
VRTX.USAVRTX.Mexico0QZU.UKVX1.GermanyVRTX.AustriaVRTX34.Brazil1VRTX.Italy Index Membership
S&P 500NASDAQ 100Russell 1000Russell 3000 IPO Date
1991-07-31Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.76 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -22.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 12.31 | |||||
| Beneish M-Score | -2.35 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.6 | |||||
| 3-Year EBITDA Growth Rate | -44.8 | |||||
| 3-Year EPS without NRI Growth Rate | -68.2 | |||||
| 3-Year Book Growth Rate | 17.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 235.65 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9.43 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.47 | |||||
| 9-Day RSI | 56.68 | |||||
| 14-Day RSI | 52.73 | |||||
| 3-1 Month Momentum % | -8.81 | |||||
| 6-1 Month Momentum % | 9.77 | |||||
| 12-1 Month Momentum % | -6.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.65 | |||||
| Quick Ratio | 2.29 | |||||
| Cash Ratio | 1.64 | |||||
| Days Inventory | 252.89 | |||||
| Days Sales Outstanding | 56.65 | |||||
| Days Payable | 90.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | 1.01 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.03 | |||||
| Operating Margin % | -3.77 | |||||
| Net Margin % | -8.91 | |||||
| EBITDA Margin % | -0.68 | |||||
| FCF Margin % | -11.33 | |||||
| ROE % | -6.04 | |||||
| ROA % | -4.43 | |||||
| ROIC % | -11.1 | |||||
| 3-Year ROIIC % | -20.61 | |||||
| ROC (Joel Greenblatt) % | -12.57 | |||||
| ROCE % | -1.49 | |||||
| Years of Profitability over Past 10-Year | 7 | |||||
| Moat score | 8 | |||||
| Tariff score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 25.44 | |||||
| Shiller PE Ratio | 68.52 | |||||
| PS Ratio | 10.67 | |||||
| PB Ratio | 7.12 | |||||
| Price-to-Tangible-Book | 7.85 | |||||
| EV-to-EBIT | -402.75 | |||||
| EV-to-Forward-EBIT | 21.71 | |||||
| EV-to-EBITDA | -1489.47 | |||||
| EV-to-Forward-EBITDA | 20.84 | |||||
| EV-to-Revenue | 10.05 | |||||
| EV-to-Forward-Revenue | 9.37 | |||||
| EV-to-FCF | -88.68 | |||||
| Price-to-GF-Value | 1.04 | |||||
| Price-to-Projected-FCF | 2.56 | |||||
| Price-to-Median-PS-Value | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 32.39 | |||||
| Earnings Yield (Greenblatt) % | -0.25 | |||||
| FCF Yield % | -1.07 | |||||
| Forward Rate of Return (Yacktman) % | -10.91 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers